SCZD
MCID: SCH015
MIFTS: 76

Schizophrenia (SCZD)

Categories: Ear diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Schizophrenia

MalaCards integrated aliases for Schizophrenia:

Name: Schizophrenia 57 11 42 75 73 28 12 53 5 41 43 14 36 38 71 31 33
Schizophrenia with or Without an Affective Disorder 57 73
Schizophrenia, Susceptibility to 57 5
Schizophrenia 12 57 71
Sczd 57 73
Dementia Praecox 42
Schizophrenia 1 71
Schizophrenia-1 11

Characteristics:


Inheritance:

Autosomal dominant 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
genetic heterogeneity
onset often in late adolescence
symptoms must occur for 6 months including 1 month of characteristic symptoms (e.g. delusions) to make diagnosis
multiple gene loci involved in causation of schizophrenia


Classifications:



External Ids:

Disease Ontology 11 DOID:5419
OMIM® 57 181500
ICD9CM 34 295
MeSH 43 D012559
NCIt 49 C3362
SNOMED-CT 68 58214004
ICD10 31 F20 F20.9
ICD11 33 1683919430
UMLS 71 C0036341 C0220702 C1837893

Summaries for Schizophrenia

MedlinePlus Genetics: 42 Schizophrenia is a brain disorder classified as a psychosis, which means that it affects a person's thinking, sense of self, and perceptions. The disorder typically becomes evident during late adolescence or early adulthood.Signs and symptoms of schizophrenia include false perceptions called hallucinations. Auditory hallucinations of voices are the most common hallucinations in schizophrenia, but affected individuals can also experience hallucinations of visions, smells, or touch (tactile) sensations. Strongly held false beliefs (delusions) are also characteristic of schizophrenia. For example, affected individuals may be certain that they are a particular historical figure or that they are being plotted against or controlled by others.People with schizophrenia often have decreased ability to function at school, at work, and in social settings. Disordered thinking and concentration, inappropriate emotional responses, erratic speech and behavior, and difficulty with personal hygiene and everyday tasks can also occur. People with schizophrenia may have diminished facial expression and animation (flat affect), and in some cases become unresponsive (catatonic). Substance abuse and suicidal thoughts and actions are common in people with schizophrenia.Certain movement problems such as tremors, facial tics, rigidity, and unusually slow movement (bradykinesia) or an inability to move (akinesia) are common in people with schizophrenia. In most cases these are side effects of medicines prescribed to help control the disorder. However, some affected individuals exhibit movement abnormalities before beginning treatment with medication.Some people with schizophrenia have mild impairment of intellectual function, but schizophrenia is not associated with the same types of physical changes in the brain that occur in people with dementias such as Alzheimer disease.Psychotic disorders such as schizophrenia are different from mood disorders, including depression and bipolar disorder, which primarily affect emotions. However, these disorders often occur together. Individuals who exhibit strong features of both schizophrenia and mood disorders are often given the diagnosis of schizoaffective disorder.

MalaCards based summary: Schizophrenia, also known as schizophrenia with or without an affective disorder, is related to schizoaffective disorder and psychotic disorder, and has symptoms including photophobia, personality changes and restlessness. An important gene associated with Schizophrenia is RTN4R (Reticulon 4 Receptor), and among its related pathways/superpathways are Methylphenidate Pathway, Pharmacodynamics and MTHFR deficiency. The drugs Celecoxib and Asenapine have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cortex, and related phenotypes are eeg abnormality and hallucinations

MedlinePlus: 41 Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms: Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. "Negative" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention. No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health

OMIM®: 57 Schizophrenia is a psychosis, a disorder of thought and sense of self. Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. There is no characteristic pathology, such as neurofibrillary tangles in Alzheimer disease (104300). Schizophrenia is a common disorder with a lifetime prevalence of approximately 1%. It is highly heritable but the genetics are complex. This may not be a single entity. Schizophrenia and bipolar disorder (see 125480) are generally considered to be separate entities, but patients who exhibit multiple symptoms of both disorders are often given the hybrid diagnosis schizoaffective disorder (Blacker and Tsuang, 1992). (181500) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: 73 A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

Disease Ontology: 11 A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness.

Wikipedia: 75 Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major... more...

Related Diseases for Schizophrenia

Diseases in the Schizophrenia family:

Schizophrenia 1 Schizophrenia 3
Schizophrenia 4 Schizophrenia 6
Schizophrenia 5 Schizophrenia 7
Schizophrenia 8 Schizophrenia 2
Schizophrenia 9 Schizophrenia 10
Schizophrenia 11 Schizophrenia 12
Schizophrenia 14 Schizophrenia 13
Schizophrenia 15 Schizophrenia 16
Schizophrenia 18 Schizophrenia 19
Early-Onset Schizophrenia

Diseases related to Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1514)
# Related Disease Score Top Affiliating Genes
1 schizoaffective disorder 34.4 SYN2 RTN4R NRXN1 MTHFR HTR2A DRD3
2 psychotic disorder 34.1 SYN2 RTN4R NRXN1 MTHFR HTR2A DRD3
3 paranoid schizophrenia 33.8 MIAT HTR2A DRD3 DISC1 COMT
4 bipolar disorder 33.6 SYN2 NRXN1 MTHFR HTR2A DRD3 DISC2
5 schizophreniform disorder 33.3 NRXN1 HTR2A DRD3 DISC1 DAOA COMT
6 schizophrenia 1 33.2 DISC1 DAOA
7 schizophrenia 18 33.2 NRXN1 DISC1
8 schizophrenia 2 33.0 DISC2 DISC1
9 tardive dyskinesia 32.9 NRXN1 DISC1 COMT
10 major depressive disorder 32.8 HTR2A DRD3 DISC2 DISC1 COMT
11 autism 32.8 SYN2 NRXN1 MTHFR MBD5 HTR2A DRD3
12 chromosome 22q11.2 deletion syndrome, distal 32.8 RTN4R NRXN1 DISC1 COMT
13 mood disorder 32.7 HTR2A DRD3 DISC2 DISC1 DAOA COMT
14 substance abuse 32.6 MIAT HTR2A DRD3 COMT
15 autism spectrum disorder 32.6 NRXN1 MTHFR MBD5 DRD3 DISC2 COMT
16 personality disorder 32.6 HTR2A DRD3 COMT
17 velocardiofacial syndrome 32.5 NRXN1 DISC1 COMT
18 schizotypal personality disorder 32.4 HTR2A DISC1 DAOA COMT
19 obsessive-compulsive disorder 32.4 HTR2A DRD3 COMT
20 attention deficit-hyperactivity disorder 32.4 NRXN1 HTR2A DRD3 DISC1 COMT
21 tobacco addiction 32.4 NRXN1 MTHFR HTR2A DRD3 COMT
22 bipolar i disorder 32.3 HTR2A DISC1 DAOA COMT
23 anxiety 32.2 HTR2A DRD3 DISC1 COMT
24 disease of mental health 32.2 NRXN1 MIR30E HTR2A DRD3 DISC1 COMT
25 delusional disorder 32.2 HTR2A DISC1 COMT
26 alzheimer disease, familial, 1 32.0 RTN4R MIR30E MIAT HTR2A DRD3 COMT
27 panic disorder 32.0 HTR2A DRD3 DAOA COMT
28 neurotic disorder 31.7 HTR2A COMT
29 gilles de la tourette syndrome 31.6 NRXN1 HTR2A DRD3 COMT
30 substance dependence 31.5 HTR2A DRD3 COMT
31 cyclothymic disorder 31.4 HTR2A DISC1 DAOA COMT
32 cannabis abuse 31.4 DISC1 COMT
33 tic disorder 31.4 NRXN1 HTR2A DRD3 COMT
34 migraine with or without aura 1 31.4 MTHFR HTR2A DRD3 COMT
35 pervasive developmental disorder 31.3 NRXN1 HTR2A DISC1
36 alexithymia 31.3 HTR2A COMT
37 polysubstance abuse 31.3 DRD3 COMT
38 oppositional defiant disorder 31.2 HTR2A DRD3 COMT
39 dissociative disorder 31.2 HTR2A COMT
40 melancholia 31.2 HTR2A COMT
41 drug psychosis 31.1 HTR2A COMT
42 pathological gambling 31.1 HTR2A DRD3 COMT
43 heroin dependence 31.0 MIAT HTR2A DRD3 COMT
44 substance-induced psychosis 31.0 HTR2A COMT
45 dysthymic disorder 31.0 HTR2A COMT
46 brunner syndrome 30.8 HTR2A COMT
47 obsessive-compulsive personality disorder 30.8 HTR2A DRD3 COMT
48 impulse control disorder 30.8 HTR2A DRD3 COMT
49 bruxism 30.6 HTR2A DRD3 COMT
50 intermittent explosive disorder 30.5 HTR2A COMT

Comorbidity relations with Schizophrenia via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease, Familial, 1 Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Heart Disease Hypothyroidism
Iron Deficiency Anemia Major Depressive Disorder
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Schizophrenia:



Diseases related to Schizophrenia

Symptoms & Phenotypes for Schizophrenia

Human phenotypes related to Schizophrenia:

30 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 eeg abnormality 30 HP:0002353
2 hallucinations 30 HP:0000738
3 schizophrenia 30 HP:0100753
4 delusions 30 HP:0000746
5 social and occupational deterioration 30 HP:0007086
6 negativism 30 HP:0410291

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neurologic Central Nervous System:
hallucinations
schizophrenia
delusions
social and occupational deterioration
disorganized speech
more
Laboratory Abnormalities:
abnormal eeg in 25% hospitalized patients

Clinical features from OMIM®:

181500 (Updated 08-Dec-2022)

UMLS symptoms related to Schizophrenia:


photophobia; personality changes; restlessness; pseudobulbar behavioral symptoms; sleep disturbances

MGI Mouse Phenotypes related to Schizophrenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 COMT DISC1 DRD3 MBD5 MIAT MIR206
2 behavior/neurological MP:0005386 9.4 COMT DISC1 DRD3 HTR2A MBD5 MIAT

Drugs & Therapeutics for Schizophrenia

Drugs for Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 163091
3
Molindone Approved Phase 4 7416-34-4 23897
4
Allopurinol Approved Phase 4 315-30-0 2094 135401907
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
9
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
10
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
11
Nizatidine Approved Phase 4 76963-41-2 3033637
12
Histamine Approved, Investigational Phase 4 51-45-6 774
13
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
14
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
15
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
16
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
17
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
18
Flunarizine Approved Phase 4 52468-60-7 941361
19
Famotidine Approved Phase 4 76824-35-6 3325 5702160
20
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
21 Coconut Approved Phase 4
22
Trifluoperazine Approved, Investigational Phase 4 440-17-5, 117-89-5 5566
23
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
24
Lorazepam Approved Phase 4 846-49-1 3958
25
Lithium carbonate Approved Phase 4 554-13-2
26
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Tocopherol Approved, Investigational Phase 4 1406-66-2
28
Valaciclovir Approved, Investigational Phase 4 124832-27-5, 124832-26-4 60773 135398742
29
Mecobalamin Approved, Investigational Phase 4 13422-55-4
30
Pramlintide Approved, Investigational Phase 4 151126-32-8 139600705 70691388
31
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
32
Pravastatin Approved Phase 4 81093-37-0 54687
33
Rasagiline Approved Phase 4 136236-51-6 3052776
34
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
35
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
36
Succinylcholine Approved Phase 4 306-40-1, 71-27-2 5314
37
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
38
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
39
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
40
Losartan Approved Phase 4 114798-26-4 3961
41
Benzatropine Approved Phase 4 86-13-5 1201549
42
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
43
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
44
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
45
Diamorphine Approved, Illicit, Investigational Phase 4 561-27-3 5462328
46
Phenol Approved, Experimental Phase 4 108-95-2 996
47
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
48
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
49
Acetaminophen Approved Phase 4 103-90-2 1983
50
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327

Interventional clinical trials:

(show top 50) (show all 2988)
# Name Status NCT ID Phase Drugs
1 Pilot Double Blind, Placebo Controlled and Randomized Study to Assess Electroconvulsive Therapy Efficacy as Augmenting Strategy to Clozapine in Super-refractory Schizophrenia Unknown status NCT02049021 Phase 4
2 An Open-label Switch Study to Asenapine in the Early Stage of Psychosis Unknown status NCT01968161 Phase 4 Asenapine
3 A Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response With Aripiprazole Once Monthly and Standard of Care Oral Antipsychotics in Non-adherent Outpatients With Schizophrenia Identified Using the Brief Adherence Rating Scale Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
4 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
5 Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
6 A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
7 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial. Unknown status NCT00395915 Phase 4 aripiprazole
8 Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia Unknown status NCT03802838 Phase 4 Amisulpride
9 The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study Unknown status NCT03080194 Phase 4 paliperidone palmitate;control group
10 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
11 Comparison of Propofol Combine Ketamine Anesthesia and Propofol Anesthesia in Schizophrenia Electroconvulsive Therapy: A Randomized Controlled Trial Unknown status NCT03829124 Phase 4 Propofol;Ketamine
12 Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients Unknown status NCT03784222 Phase 4 Blonanserin
13 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Unknown status NCT03881449 Phase 4
14 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
15 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
16 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
17 Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
18 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics
19 Transcranial Magnetic Stimulation Used to Treat Auditory Hallucinations in Schizophrenia Unknown status NCT00186771 Phase 4
20 A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus. Unknown status NCT00182494 Phase 4
21 Effect of Anti-inflammatory Treatments on the Symptoms, Cognition, and Functioning of Adolescents With Schizophrenia Unknown status NCT04020588 Phase 4 Celecoxib 200mg;Placebo oral capsule;Minocycline 100mg
22 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
23 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
24 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
25 Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
26 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
27 Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4 Donepezil;placebo
28 A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? Unknown status NCT01481883 Phase 4 Raloxifene Hydrochloride;Placebo
29 Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
30 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Unknown status NCT03495024 Phase 4 Varenicline
31 Omega-3 Fatty Acids in First-episode Schizophrenia - a Randomized Controlled Study of Efficacy and Relapse Prevention (OFFER). Rationale, Design, and Methods. Unknown status NCT02210962 Phase 4
32 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
33 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up Unknown status NCT03090503 Phase 4 Aripiprazole;Risperidone
34 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years Unknown status NCT03883204 Phase 4 Aripiprazole;Risperidone
35 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
36 Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
37 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
38 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up Unknown status NCT02532491 Phase 4 Aripiprazole;Risperidone
39 Estimating the Optimal Dynamic Antipsychotic Treatment Regime: Sequential Multiple-assignment Randomized Clinical Antipsychotic Trials in Chinese Patients With First-episode Psychosis. Unknown status NCT03510325 Phase 4 Olanzapine;Risperidone;Aripiprazole;Amisulpride;Paliperidone long-acting injection
40 A Double-blind, Randomized, Placebo Controlled Clinical Trial on Comparing Escitalopram and Duloxetine add-on for Negative Symptoms in Schizophrenic Subjects With Neuregulin-1 (NRG1) Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
41 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
42 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
43 Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
44 Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
45 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
46 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
47 Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia Completed NCT00864825 Phase 4 Allopurinol
48 Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up Completed NCT01685931 Phase 4 Paliperidone Palmitate
49 Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities Completed NCT02751307 Phase 4 metformin 500 mg;clozapine 100 mg
50 Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial) Completed NCT00014001 Phase 4 perphenazine;olanzapine;quetiapine;risperidone;ziprasidone;clozapine;fluphenazine decanoate

Search NIH Clinical Center for Schizophrenia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


acetophenazine
Acetophenazine maleate
aripiprazole
aripiprazole lauroxil
Carbamazepine
Chlorpromazine
Chlorpromazine hydrochloride
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Cyproheptadine
Cyproheptadine hydrochloride
CYPROHEPTADINE HYDROCHLORIDE MONOHYDRATE
deserpidine
Fazaclo
Fluphenazine
fluphenazine decanoate
Fluphenazine enanthate
Fluphenazine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
Mesoridazine
Mesoridazine besylate
Molindone
Molindone Hydrochloride
Mylan brand of clozapine
olanzapine
Perphenazine
piperacetazine
Reserpine
Risperidone
Selegiline
selegiline hydrochloride
Thioridazine
Thioridazine Hydrochloride
Thiothixene
Thiothixene hydrochloride
Trifluoperazine
Trifluoperazine hydrochloride
UDL brand of clozapine
ziprasidone
ziprasidone hydrochloride
Ziprasidone mesylate

Cochrane evidence based reviews: schizophrenia

Genetic Tests for Schizophrenia

Genetic tests related to Schizophrenia:

# Genetic test Affiliating Genes
1 Schizophrenia 28 APOL2 APOL4 CHI3L1 COMT DAOA DISC2 DRD3 HTR2A MTHFR RTN4R SYN2

Anatomical Context for Schizophrenia

Organs/tissues related to Schizophrenia:

MalaCards : Brain, Prefrontal Cortex, Cortex, Cingulate Cortex, Temporal Lobe, Globus Pallidus, Thalamus

Publications for Schizophrenia

Articles related to Schizophrenia:

(show top 50) (show all 32296)
# Title Authors PMID Year
1
Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. 53 62 57 5
15532024 2004
2
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. 62 57 5
18583979 2008
3
Common variants conferring risk of schizophrenia. 53 62 57
19571808 2009
4
Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate. 53 62 57
19077434 2009
5
The DISC locus in psychiatric illness. 53 62 57
17912248 2008
6
Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. 53 62 57
16767099 2006
7
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. 53 62 57
16513877 2006
8
DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. 53 62 57
16293762 2005
9
Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. 53 62 57
16146415 2005
10
Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. 53 62 57
15806605 2005
11
Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. 53 62 57
15707951 2005
12
Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. 53 62 5
15645182 2005
13
Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. 53 62 57
15381923 2005
14
BDNF gene is a risk factor for schizophrenia in a Scottish population. 53 62 57
15630410 2005
15
Association of the DTNBP1 locus with schizophrenia in a U.S. population. 53 62 57
15362017 2004
16
Replication of 1q42 linkage in Finnish schizophrenia pedigrees. 53 62 57
15197400 2004
17
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. 53 62 57
15386212 2004
18
Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families. 53 62 57
15274033 2004
19
Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. 53 62 57
15065015 2004
20
Confirming RGS4 as a susceptibility gene for schizophrenia. 53 62 57
14755443 2004
21
Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. 53 62 57
14532331 2003
22
Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. 53 62 57
12611827 2003
23
A highly significant association between a COMT haplotype and schizophrenia. 53 62 57
12402217 2002
24
Association and linkage analyses of RGS4 polymorphisms in schizophrenia. 53 62 57
12023979 2002
25
Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. 53 62 57
11930015 2002
26
Chromosome 1 loci in Finnish schizophrenia families. 53 62 57
11468279 2001
27
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. 53 62 57
11326297 2001
28
Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. 53 62 57
11086983 2000
29
A decrease of reelin expression as a putative vulnerability factor in schizophrenia. 53 62 57
9861036 1998
30
Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. 53 62 5
8622505 1996
31
Genetics of schizophrenia in the South African Xhosa. 62 57
32001654 2020
32
Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights. 62 5
30208311 2018
33
Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. 62 5
26974950 2016
34
Biological insights from 108 schizophrenia-associated genetic loci. 62 57
25056061 2014
35
A polygenic burden of rare disruptive mutations in schizophrenia. 62 57
24463508 2014
36
De novo mutations in schizophrenia implicate synaptic networks. 62 57
24463507 2014
37
De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. 62 57
23042115 2012
38
Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problems. 62 57
21792059 2011
39
Exome sequencing supports a de novo mutational paradigm for schizophrenia. 62 57
21822266 2011
40
Increased exonic de novo mutation rate in individuals with schizophrenia. 62 57
21743468 2011
41
Modelling schizophrenia using human induced pluripotent stem cells. 62 57
21490598 2011
42
Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. 62 57
21055719 2010
43
Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. 62 57
20797689 2010
44
Microdeletions of 3q29 confer high risk for schizophrenia. 62 57
20691406 2010
45
De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. 62 57
20385823 2010
46
Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. 62 57
19883952 2009
47
A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. 62 57
19944402 2009
48
Schizophrenia. 62 57
19700006 2009
49
Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. 62 57
19255043 2009
50
Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. 62 57
19181681 2009

Variations for Schizophrenia

ClinVar genetic disease variations for Schizophrenia:

5 (show top 50) (show all 211)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SETD1A NM_014712.3(SETD1A):c.1272del (p.Tyr425fs) DEL Pathogenic
224651 rs869312830 GRCh37: 16:30976335-30976335
GRCh38: 16:30965014-30965014
2 SETD1A NM_014712.3(SETD1A):c.1938C>G (p.Tyr646Ter) SNV Pathogenic
224654 rs770913157 GRCh37: 16:30977140-30977140
GRCh38: 16:30965819-30965819
3 SETD1A NM_014712.3(SETD1A):c.2209C>T (p.Gln737Ter) SNV Pathogenic
224652 rs869312831 GRCh37: 16:30977411-30977411
GRCh38: 16:30966090-30966090
4 SETD1A NM_014712.3(SETD1A):c.518-2A>G SNV Pathogenic
224650 rs869312829 GRCh37: 16:30974752-30974752
GRCh38: 16:30963431-30963431
5 SETD1A NM_014712.3(SETD1A):c.2171dup (p.Ala725fs) DUP Pathogenic
224653 rs869312832 GRCh37: 16:30977372-30977373
GRCh38: 16:30966051-30966052
6 overlap with 59 genes NC_000001.11:g.(?_145430995)_(148257619_?)del DEL Pathogenic
545142 GRCh37:
GRCh38: 1:145430995-148257619
7 overlap with 70 genes NC_000001.11:g.(?_145430995)_(148427734_?)del DEL Pathogenic
545143 GRCh37:
GRCh38: 1:145430995-148427734
8 overlap with 76 genes NC_000001.11:g.(?_145580669)_(149095000_?)del DEL Pathogenic
545144 GRCh37:
GRCh38: 1:145580669-149095000
9 overlap with 10 genes NC_000015.10:g.(?_22444190)_(23226874_?)del DEL Pathogenic
545164 GRCh37:
GRCh38: 15:22444190-23226874
10 overlap with 9 genes NC_000015.10:g.(?_22673143)_(23226874_?)del DEL Pathogenic
545166 GRCh37:
GRCh38: 15:22673143-23226874
11 overlap with 7 genes NC_000015.10:g.(?_22673675)_(23126124_?)del DEL Pathogenic
545167 GRCh37:
GRCh38: 15:22673675-23126124
12 overlap with 9 genes NC_000015.10:g.(?_22681827)_(23226874_?)del DEL Pathogenic
545168 GRCh37:
GRCh38: 15:22681827-23226874
13 overlap with 7 genes NC_000015.10:g.(?_22751662)_(23126124_?)del DEL Pathogenic
545169 GRCh37:
GRCh38: 15:22751662-23126124
14 overlap with 7 genes NC_000015.10:g.(?_22770232)_(23126124_?)del DEL Pathogenic
545170 GRCh37:
GRCh38: 15:22770232-23126124
15 overlap with 132 genes DUP Pathogenic
545171 GRCh37:
GRCh38: 15:23157975-28774125
16 overlap with 130 genes DUP Pathogenic
545172 GRCh37:
GRCh38: 15:23319712-28684313
17 overlap with 26 genes NC_000015.10:g.(?_30325774)_(32194551_?)del DEL Pathogenic
545177 GRCh37:
GRCh38: 15:30325774-32194551
18 overlap with 30 genes NC_000016.10:g.(?_28351819)_(29325073_?)del DEL Pathogenic
545197 GRCh37:
GRCh38: 16:28351819-29325073
19 overlap with 46 genes DUP Pathogenic
545200 GRCh37:
GRCh38: 16:29480853-30254620
20 overlap with 38 genes DUP Pathogenic
545202 GRCh37:
GRCh38: 16:29614026-30184960
21 overlap with 38 genes NC_000016.10:g.(?_29627836)_(30184960_?)del DEL Pathogenic
545203 GRCh37:
GRCh38: 16:29627836-30184960
22 overlap with 38 genes DUP Pathogenic
545204 GRCh37:
GRCh38: 16:29627836-30184960
23 overlap with 38 genes DUP Pathogenic
545205 GRCh37:
GRCh38: 16:29640511-30184960
24 overlap with 26 genes NC_000017.11:g.(?_36357256)_(37995300_?)del DEL Pathogenic
545220 GRCh37:
GRCh38: 17:36357256-37995300
25 overlap with 2 genes NC_000002.12:g.(?_147990605)_(148350066_?)del DEL Pathogenic
545246 GRCh37:
GRCh38: 2:147990605-148350066
26 MBD5 NC_000002.12:g.(?_148139385)_(148242336_?)del DEL Pathogenic
545247 GRCh37:
GRCh38: 2:148139385-148242336
27 MBD5 NC_000002.12:g.(?_148157591)_(148226058_?)del DEL Pathogenic
545248 GRCh37:
GRCh38: 2:148157591-148226058
28 MBD5 NC_000002.12:g.(?_148158424)_(148226279_?)del DEL Pathogenic
545249 GRCh37:
GRCh38: 2:148158424-148226279
29 MBD5 NC_000002.12:g.(?_148211972)_(148423169_?)del DEL Pathogenic
545250 GRCh37:
GRCh38: 2:148211972-148423169
30 overlap with 46 genes NC_000003.12:g.(?_195990063)_(197617301_?)del DEL Pathogenic
545294 GRCh37:
GRCh38: 3:195990063-197617301
31 overlap with 38 genes NC_000003.12:g.(?_196154147)_(197376501_?)del DEL Pathogenic
545295 GRCh37:
GRCh38: 3:196154147-197376501
32 overlap with 46 genes DUP Pathogenic
545349 GRCh37:
GRCh38: 7:73312644-74726596
33 overlap with 96 genes NC_000022.11:g.(?_18159879)_(21362822_?)del DEL Pathogenic
545256 GRCh37:
GRCh38: 22:18159879-21362822
34 overlap with 97 genes NC_000022.11:g.(?_18159879)_(21387988_?)del DEL Pathogenic
545257 GRCh37:
GRCh38: 22:18159879-21387988
35 overlap with 93 genes NC_000022.11:g.(?_18163926)_(21277123_?)del DEL Pathogenic
545258 GRCh37:
GRCh38: 22:18163926-21277123
36 overlap with 85 genes NC_000022.11:g.(?_18802709)_(21343709_?)del DEL Pathogenic
545259 GRCh37:
GRCh38: 22:18802709-21343709
37 overlap with 82 genes NC_000022.11:g.(?_18832909)_(21123588_?)del DEL Pathogenic
545260 GRCh37:
GRCh38: 22:18832909-21123588
38 overlap with 84 genes NC_000022.11:g.(?_18846939)_(21221413_?)del DEL Pathogenic
545261 GRCh37:
GRCh38: 22:18846939-21221413
39 overlap with 60 genes NC_000022.11:g.(?_18880919)_(20346734_?)del DEL Pathogenic
545262 GRCh37:
GRCh38: 22:18880919-20346734
40 overlap with 82 genes NC_000022.11:g.(?_18880919)_(21123588_?)del DEL Pathogenic
545263 GRCh37:
GRCh38: 22:18880919-21123588
41 NRXN1 NC_000002.12:g.(?_50721552)_(50944617_?)del DEL Pathogenic
545279 GRCh37:
GRCh38: 2:50721552-50944617
42 overlap with 2 genes NC_000002.12:g.(?_50836961)_(51084060_?)del DEL Pathogenic
545280 GRCh37:
GRCh38: 2:50836961-51084060
43 overlap with 2 genes NC_000002.12:g.(?_50975328)_(51121693_?)del DEL Pathogenic
545281 GRCh37:
GRCh38: 2:50975328-51121693
44 overlap with 38 genes GRCh37/hg19 22q11.21(chr22:19036286-21208284)x1 CN LOSS Pathogenic
1330206 GRCh37: 22:19036286-21208284
GRCh38:
45 SETD1A NM_014712.3(SETD1A):c.757C>T (p.Arg253Ter) SNV Pathogenic
1330308 GRCh37: 16:30975532-30975532
GRCh38: 16:30964211-30964211
46 IRAK1BP1, PHIP NM_017934.7(PHIP):c.4174_4175insATTTTCAGTAATTATTTTCAGTAATT (p.Ser1392delinsTyrPheGlnTer) MICROSAT Pathogenic
1339462 GRCh37: 6:79657371-79657372
GRCh38: 6:78947654-78947655
47 overlap with 45 genes NC_000016.10:g.(?_14780667)_(16415941_?)del DEL Pathogenic
545186 GRCh37:
GRCh38: 16:14780667-16415941
48 overlap with 35 genes DUP Pathogenic
545187 GRCh37:
GRCh38: 16:15029830-16415941
49 overlap with 35 genes DUP Pathogenic
545188 GRCh37:
GRCh38: 16:15030738-16517711
50 overlap with 48 genes DUP Pathogenic
545189 GRCh37:
GRCh38: 16:15085515-18775195

UniProtKB/Swiss-Prot genetic disease variations for Schizophrenia:

73
# Symbol AA change Variation ID SNP ID
1 RTN4R p.Arg119Trp VAR_079154 rs74315508
2 RTN4R p.Arg196His VAR_079155 rs74315509
3 RTN4R p.Arg292His VAR_079231 rs1432033565
4 RTN4R p.Arg377Gln VAR_079235 rs779384862
5 RTN4R p.Arg377Trp VAR_079236 rs748655075

Copy number variations for Schizophrenia from CNVD:

6 (show top 50) (show all 5299)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13368 1 1 16700000 Deletion Schizophrenia
2 13397 1 1 2300000 Gain OR4F16 Schizophrenia
3 13398 1 1 2300000 Gain OR4F29 Schizophrenia
4 13399 1 1 2300000 Gain OR4F3 Schizophrenia
5 13400 1 1 2300000 Gain OR4F5 Schizophrenia
6 13737 1 1 247249719 Deletion Schizophrenia
7 13808 1 1 6300000 Copy number Schizophrenia
8 13997 1 102428272 102625426 Deletion Schizophrenia
9 14001 1 102628520 102630703 Deletion Schizophrenia
10 14084 1 103900163 104069733 Duplication Schizophrenia
11 14085 1 103904299 104069733 Duplication Schizophrenia
12 14102 1 103957313 104069733 Deletion Schizophrenia
13 14103 1 103957313 104069733 Duplication Schizophrenia
14 14105 1 103958672 104069733 Deletion Schizophrenia
15 14106 1 103959820 104069733 Deletion Schizophrenia
16 14107 1 103960858 104069733 Deletion Schizophrenia
17 14335 1 107200000 111800000 Copy number Schizophrenia
18 14450 1 108512791 108702882 Deletion Schizophrenia
19 15499 1 1161232 1266721 Deletion Schizophrenia
20 15950 1 120437237 120490996 Duplication Schizophrenia
21 15994 1 120870371 121045604 Duplication Schizophrenia
22 16564 1 12768438 12920855 Deletion Schizophrenia
23 16565 1 12768438 13081658 Deletion Schizophrenia
24 16566 1 12768438 13304227 Deletion Schizophrenia
25 16576 1 12775335 12920855 Deletion Schizophrenia
26 17280 1 142400000 148000000 Copy number Schizophrenia
27 17281 1 142400000 148000000 Copy number Schizophrenia
28 17287 1 142400000 148000000 Deletion Schizophrenia
29 17288 1 142400000 148000000 Deletion Schizophrenia
30 17289 1 142400000 148000000 Deletion Schizophrenia
31 17290 1 142400000 148000000 Deletion Schizophrenia
32 17291 1 142400000 148000000 Deletion Schizophrenia
33 17292 1 142400000 148000000 Deletion Schizophrenia
34 17311 1 142400000 148000000 Gain FCGR1A Schizophrenia
35 17313 1 142400000 148000000 Gain H2BC18 Schizophrenia
36 17315 1 142400000 148000000 Gain PPIAL4A Schizophrenia
37 17331 1 142400000 148000000 Microduplication Schizophrenia
38 17358 1 142557948 142697860 Duplication Schizophrenia
39 17373 1 142600000 147000000 Copy number Schizophrenia
40 17379 1 142600000 147000000 Deletion Schizophrenia
41 17380 1 142600000 147000000 Deletion Schizophrenia
42 17381 1 142600000 147000000 Deletion Schizophrenia
43 17382 1 142600000 147000000 Deletion Schizophrenia
44 17386 1 142600000 147000000 Deletion or duplication Schizophrenia
45 17394 1 142600000 155000000 Deletion Schizophrenia
46 17444 1 142803849 143666594 Duplication Schizophrenia
47 18122 1 144106312 146292286 Deletion Schizophrenia
48 18123 1 144106312 146293282 Deletion Schizophrenia
49 18129 1 144149818 144153985 Copy number TXNIP Schizophrenia
50 18137 1 144188441 144210448 Gain LIX1L Schizophrenia

Expression for Schizophrenia

Search GEO for disease gene expression data for Schizophrenia.

Pathways for Schizophrenia



Pathways directly related to Schizophrenia:

# Pathway Source
1 Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) Reactome 66

Pathways related to Schizophrenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.32 DRD3 COMT
2 9.95 MTHFR COMT

GO Terms for Schizophrenia

Cellular components related to Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.86 SYN2 NRXN1 MTHFR HTR2A DRD3 DISC1
2 GABA-ergic synapse GO:0098982 9.46 NRXN1 DRD3 DISC1
3 presynapse GO:0098793 9.35 RTN4R NRXN1 HTR2A DISC1
4 glutamatergic synapse GO:0098978 9.32 SYN2 RTN4R NRXN1 HTR2A DRD3 DISC1

Biological processes related to Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 behavioral response to cocaine GO:0048148 9.62 HTR2A DRD3
2 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.46 HTR2A DRD3
3 prepulse inhibition GO:0060134 9.43 NRXN1 DRD3
4 synaptic vesicle clustering GO:0097091 9.13 SYN2 NRXN1
5 neuronal signal transduction GO:0023041 8.8 RTN4R NRXN1

Sources for Schizophrenia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....